The human brain doubled in power, very suddenly, 200,000 years ago. Why?

A long-ridiculed theory about humankind's early leap of consciousness is revived.

The human brain doubled in power, very suddenly, 200,000 years ago. Why?
Photo credit: Elena Schweitzer / procy / Shutterstock / Big Think
  • Terence McKenna first proposed psychedelic mushrooms as the trigger for our rapid cognitive evolution.
  • McKenna's theory was called the "Stoned Ape Hypothesis."
  • The hypothesis is being revisited as a possible answer to a vexxing evolutionary riddle.

There seems to have been a profound difference in cognitive abilities between early Homo sapiens and our immediate predecessor, Homo erectus. Sure, erectus stood upright — a big, um, step forward — but with the emergence of Homo sapiens, we see traces of art, pictography, and tool usage, and we believe humankind made its first forays into language.

In the early 1990s, psychedelic advocate and ethnobotanist Terence McKenna published his book Food of the Gods in which he surmised that homo sapiens' cognitive leap forward was due to their discovery of magic mushrooms. The scientific community never took McKenna's theory very seriously, considering it mostly trippy speculation — these days, his ideas have largely been relegated to the spacier corners of Reddit. Now, however, the idea has acquired a new advocate, psilocybin mycologist Paul Stamets, who's suggesting McKenna was right all along.

The stoned ape

Terence McKenna. Image source: Jon Hanna/Wikimedia

In McKenna's Stoned Ape hypothesis," he posited that as humans began to migrate to new areas, at some point they came upon psychedelic mushrooms growing in cow droppings, as is their wont, and then ate them. After ingesting them, and more specifically the psilocybin they contained, their brains kicked into overdrive, acquiring new information-processing capabilities, and a mind-blowing expansion of our imaginations in the bargain. Many modern users of psychedelics claim the world never looks the same again after such an experience. As McKenna put it, "Homo sapiens ate our way to a higher consciousness," and, "It was at this time that religious ritual, calendar making, and natural magic came into their own."

The return of the stoned ape

Image source: Chris Moody / Shutterstock / Big Think

Regarding this theory, Stamets presented "Psilocybin Mushrooms and the Mycology of Consciousness" at Psychedelic Science 2017. In his talk he sought to rehabilitate McKenna's hypothesis as a totally plausible answer to a longstanding evolutionary riddle. "What is really important for you to understand," he said, "is that there was a sudden doubling of the human brain 200,000 years ago. From an evolutionary point of view, that's an extraordinary expansion. And there is no explanation for this sudden increase in the human brain."

Why not mushrooms? Stamets portrayed a group of early humans making their way through the savannah and happening across "the largest psilocybin mushroom in the world growing bodaciously out of dung of the animals." It needn't have been unusually large to have its effect, of course. In any event, he invited the crowd to suspend their disbelief and admit that McKenna's idea constitutes a "very, very plausible hypothesis for the sudden evolution of Homo sapiens from our primate relatives," even if it's an unprovable one.

The audience's response was reportedly enthusiastic, though it's fair to note that these were people attending a conference on psychedelic science, and thus pre-disposed toward such chemicals' importance.

Just tripping?

Image source: Apple2499 / Shutterstock

Certainly, there's general agreement on the mystery Stamets cited, if not so much on timing details. And consciousness, the "hard problem" even in its modern form, is an area rife with unanswered questions. What is consciousness, anyway? Is it a simple enough thing that it could have a single root cause as McKenna and Stamets say? Many experts suspect our brains gained new capabilities as the result of early community ties and the requirements of social interaction, but when?

Anthropologist Ian Tattersall tells Inverse that the where seems obvious enough: Africa, "For it is in this continent that we find the first glimmerings of 'modern behaviors'. . . But the moment of transformation still eludes us and may well do so almost indefinitely."

There are other researchers who've studied early humanity's use of drug plants but who are skeptical of the stoned ape notiion. Elisa Guerra-Doce, an expert in the field, considers the idea too simplistic, potentially a reduction of a complex evolutionary process into a single "aha" — or maybe "oh, wow" — moment. She's also troubled by there being little evidence of such a pivotal moment, or of drug use at all, so early in the archeological record.

Amanda Feilding of the psychedelic think tank Beckley Foundation says, however, that the stoned ape theory is at the very least a valid reminder that humans have always been drawn to and fascinated by mind-altering substances: "The imagery that comes with the psychedelic experience is a theme that runs through ancient art, so I'm sure that psychedelic experience and other techniques, like dancing and music, were used by our early ancestors to enhance consciousness, which then facilitated spirituality, art, and medicine."

Just how early our love affair with hallucinogenic states began may have something to say about the plausibility of McKenna's hypothesis, but, alas, we don't know when that would have been. And, as the saying about the 1960s goes, even if any of these people were still around to ask, anyone who was really there wouldn't be able to remember.

A new study says it's okay to eat red meat. An immediate uproar follows.

Even before publication, health agencies were asking the journal not to publish the research.

Photo by Isa Terli/Anadolu Agency/Getty Images

Surprising Science
  • A new study in the Annals of Internal Medicine found little correlation between red meat consumption and health problems.
  • A number of organizations immediately contested the evidence, claiming it to be based on an irrelevant system of analysis.
  • Beef and dairy production is one of the leading drivers of climate change, forcing humans to weigh personal health against the environment.
Keep reading Show less

CRISPR therapy cures first genetic disorder inside the body

It marks a breakthrough in using gene editing to treat diseases.

Credit: National Cancer Institute via Unsplash
Technology & Innovation

This article was originally published by our sister site, Freethink.

For the first time, researchers appear to have effectively treated a genetic disorder by directly injecting a CRISPR therapy into patients' bloodstreams — overcoming one of the biggest hurdles to curing diseases with the gene editing technology.

The therapy appears to be astonishingly effective, editing nearly every cell in the liver to stop a disease-causing mutation.

The challenge: CRISPR gives us the ability to correct genetic mutations, and given that such mutations are responsible for more than 6,000 human diseases, the tech has the potential to dramatically improve human health.

One way to use CRISPR to treat diseases is to remove affected cells from a patient, edit out the mutation in the lab, and place the cells back in the body to replicate — that's how one team functionally cured people with the blood disorder sickle cell anemia, editing and then infusing bone marrow cells.

Bone marrow is a special case, though, and many mutations cause disease in organs that are harder to fix.

Another option is to insert the CRISPR system itself into the body so that it can make edits directly in the affected organs (that's only been attempted once, in an ongoing study in which people had a CRISPR therapy injected into their eyes to treat a rare vision disorder).

Injecting a CRISPR therapy right into the bloodstream has been a problem, though, because the therapy has to find the right cells to edit. An inherited mutation will be in the DNA of every cell of your body, but if it only causes disease in the liver, you don't want your therapy being used up in the pancreas or kidneys.

A new CRISPR therapy: Now, researchers from Intellia Therapeutics and Regeneron Pharmaceuticals have demonstrated for the first time that a CRISPR therapy delivered into the bloodstream can travel to desired tissues to make edits.

We can overcome one of the biggest challenges with applying CRISPR clinically.

—JENNIFER DOUDNA

"This is a major milestone for patients," Jennifer Doudna, co-developer of CRISPR, who wasn't involved in the trial, told NPR.

"While these are early data, they show us that we can overcome one of the biggest challenges with applying CRISPR clinically so far, which is being able to deliver it systemically and get it to the right place," she continued.

What they did: During a phase 1 clinical trial, Intellia researchers injected a CRISPR therapy dubbed NTLA-2001 into the bloodstreams of six people with a rare, potentially fatal genetic disorder called transthyretin amyloidosis.

The livers of people with transthyretin amyloidosis produce a destructive protein, and the CRISPR therapy was designed to target the gene that makes the protein and halt its production. After just one injection of NTLA-2001, the three patients given a higher dose saw their levels of the protein drop by 80% to 96%.

A better option: The CRISPR therapy produced only mild adverse effects and did lower the protein levels, but we don't know yet if the effect will be permanent. It'll also be a few months before we know if the therapy can alleviate the symptoms of transthyretin amyloidosis.

This is a wonderful day for the future of gene-editing as a medicine.

—FYODOR URNOV

If everything goes as hoped, though, NTLA-2001 could one day offer a better treatment option for transthyretin amyloidosis than a currently approved medication, patisiran, which only reduces toxic protein levels by 81% and must be injected regularly.

Looking ahead: Even more exciting than NTLA-2001's potential impact on transthyretin amyloidosis, though, is the knowledge that we may be able to use CRISPR injections to treat other genetic disorders that are difficult to target directly, such as heart or brain diseases.

"This is a wonderful day for the future of gene-editing as a medicine," Fyodor Urnov, a UC Berkeley professor of genetics, who wasn't involved in the trial, told NPR. "We as a species are watching this remarkable new show called: our gene-edited future."

UFOs: US intelligence report finds no aliens but plenty of unidentified flying objects

A new government report describes 144 sightings of unidentified aerial phenomena.

Photo by Albert Antony on Unsplash
Surprising Science

On June 25, 2021, the Office of the Director of National Intelligence released a much-anticipated report on UFOs to Congress.

Keep reading Show less
Quantcast